-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135

Benzinga·05/28/2026 18:08:49
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $110 to $135.